CJC-1295 research guide for Agassiz. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Agassiz searching for CJC-1295, the foundational reality is that this compound is available only through an online research supply market. The practical takeaway for Agassiz researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is identical for researchers everywhere. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. This guide walks Agassiz researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Agassiz studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying CJC-1295: Quality Markers to Look For
The first step for any Agassiz researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — organic rankings are no guide to actual CJC-1295 quality. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger severe inflammatory responses even at minute levels. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Agassiz
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and small-scale human observations. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
